EATONTOWN, NJ / ACCESSWIRE / October 3, 2016 / American CryoStem Corporation (OTC: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the licensing of its flagship xeno-free human mesenchymal cell culture medium, ACSelerate-Max™ for production and distribution by PeproTech, Inc., a leading manufacturer and distributor of high quality reagents, proteins and other biologic products for the life science and cell therapy markets.
ACSelerate-Max™ will be manufactured and distributed globally under the PeproTech brand from PeproTech's, Rocky Hill, NJ facility. ACSelerate-MAX™ is a patented xeno-free (animal free), completely humanized growth medium which sustains exceptional growth of mesenchymal stem cells while maintaining multipotency. Specific terms of the deal were not disclosed.
According to Grand View Research; global cell culture market size was valued at USD 16.35 billion in 2014. Usage of cell cultures has increased to an extent where conventional manual small scale production and handling of cultures is no longer enough to meet the new age production demands. The continued development of cell culture techniques and applications has poised this market to expect a steady and substantial growth through to 2022. Global cell culture market is expected to grow at a CAGR of over 10.7% during the forecast period, to reach USD 37.0 billion in 2022.
John S. Arnone, CEO stated, "ACSelerate-Max™ is the cornerstone cell culture product in the Company's portfolio of fourteen (14) patented medium products which include cell differentiation, cell transportation, cell growth and other mediums. With the continued expansion of regenerative medicine and the cell culture market, we see an opportunity for the Company to leverage its medium portfolio for global commercialization and distribution with a leading biotech, cytokine products company that has reach into 80% of the cellular research institutions globally," Arnone stated.
Michael L. Moeller, PhD, Chief Scientist of American CryoStem stated that, "Extensive testing has shown that ACSelerate-MAX™ out performs other solutions currently available in the marketplace. We believe that this medium will permit mesenchymal stem cell research projects to be completed more rapidly and consistently while allowing the stem cells to maintain full multipotency. Industry literature frequently reports cell doubling times of 72-96 hrs. for mesenchymal stem cells, but ACSelerate-MAX™ has enabled us to routinely achieve doubling times of less than 24 hours. We see this as being a tremendous benefit to researchers saving time and money."
"PeproTech is excited to use our advanced manufacturing and global distribution capabilities to bring this innovative Mesenchymal Stem Cell Media to the wider market," said Asaf Shiloni, Vice President of Sales and Business Development at PeproTech. "The co-developed MSC Media is a superior solution, one that fits PeproTech's focus on producing robust products that our customers can rely upon to efficiently deliver consistent clinical results. As a leading manufacturer of cytokines and growth factors, we're excited to add this innovative solution to our growing portfolio of stem cell media offerings."
"American CryoStem's initial licensing of it medium products represents an extension of the Company's ongoing licensing and product distribution efforts. The Company also plans to make single donor human adipose derived stem cells available for purchaser alongside a complete line of medium products," stated Anthony Dudzinski, COO of American CryoStem.
About PeproTech
PeproTech is a privately held manufacturer of high quality cytokine products for the life science and cell therapy markets. Since 1988, our unwavering focus on quality and customer service has fueled our growth from a small North American company into a global enterprise, leading the field, with state-of-the-art manufacturing facilities. PeproTech's dedicated scientists, innovative protocols, and reliable products have made our name synonymous with quality, reliability and consistency around the world.
For more information please visit: https://www.peprotech.com.
About American CryoStem Corporation
Founded in 2008, American CryoStem is a biotechnology pioneer, standardizing adipose tissue derived technologies for the fields of Regenerative and Personalized Medicine. The Company maintains a portfolio of intellectual property and operates a state-of-art, FDA-registered, clinical laboratory in Princeton, NJ dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue (fat) and adipose derived stem cells (ADSCs) for use in the Regenerative and Personalized Medicine industries. Leveraging its laboratory platform the Company is creating a global footprint of licensed laboratory affiliates and physicians networks utilizing our operating platform. The Company maintains licensed affiliates in Hong Kong, Tokyo, Japan and Shenzhen, China who purchase consumables from the Company to deliver current and future cellular applications in their territory.
For more information please visit: www.americancryostem.com.
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
For More Information:
American CryoStem
732-747-1007 or via email at [email protected]
SOURCE: American CryoStem Corporation